FDA sends CRL on Cingulate (NASDAQ: CING) ADHD drug CTx-1301
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cingulate Inc. reported that the FDA has issued a Complete Response Letter for its New Drug Application for CTx-1301, a once-daily ADHD treatment. The letter centers on specific Chemistry, Manufacturing and Controls information requests and currently does not raise concerns about clinical safety or efficacy.
The company plans a prompt resubmission to address the FDA’s requests and continue pre-commercial work. Management highlights nearly $30 million in cash reserves, which they believe is enough to complete the additional CMC work, support resubmission, and fund activities into 2027.
Positive
- None.
Negative
- FDA Complete Response Letter for CTx-1301: The NDA for CTx-1301 was not approved by the PDUFA target date, and the drug cannot be marketed until Cingulate resolves Chemistry, Manufacturing and Controls information requests and the FDA completes a subsequent review.
Insights
FDA’s CTx-1301 rejection is a setback, but issues appear limited to manufacturing data.
The FDA’s Complete Response Letter means CTx-1301 was not approved by the initial Prescription Drug User Fee Act target date and cannot be marketed yet. However, the agency’s feedback is focused on Chemistry, Manufacturing and Controls information, not on trial results.
The absence of current safety or efficacy concerns reduces the risk of costly new clinical trials, but the timing and outcome of resubmission still depend on successfully completing the CMC work with partners. Execution quality on these manufacturing and documentation tasks will shape the eventual regulatory path.
Cingulate cites nearly $30 million in cash reserves to support the additional work, resubmission, and pre-commercial activities into 2027. Investors will likely focus on future updates describing when the company resubmits the NDA and how the FDA responds to the new CMC package.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash reserves: nearly $30 million
PDUFA target action date: May 31, 2026
U.S. ADHD market size: 100 million annual prescriptions
+2 more
5 metrics
Cash reserves
nearly $30 million
Cash on hand to support CMC work, resubmission and pre-commercial activities into 2027
PDUFA target action date
May 31, 2026
Original FDA target action date for the CTx-1301 NDA
U.S. ADHD market size
100 million annual prescriptions
Estimated annual prescription volume for ADHD treatments in the U.S.
Diagnosed ADHD patients in U.S.
over 20 million
Includes 12 million adults and over 8 million under age 17
Children/teens treated with medication
53.6%
Share of children and teens with ADHD using medication in 2022
Key Terms
Complete Response Letter, New Drug Application, Chemistry, Manufacturing and Controls, Precision Timed Release, +2 more
6 terms
Complete Response Letter regulatory
"the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter"
A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.
New Drug Application regulatory
"for its New Drug Application (“NDA”) for CTx-1301 (dexmethylphenidate HCl)"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
Chemistry, Manufacturing and Controls regulatory
"The response identified specific Chemistry, Manufacturing and Controls (CMC) information requests"
Chemistry, manufacturing and controls (CMC) is the package of technical information that explains how a drug or biologic is made, tested and kept consistent, submitted to regulators to demonstrate the product’s safety, purity and reliable production. Investors care because robust CMC lowers the risk of manufacturing delays, regulatory rejection or costly recalls — think of it as the product’s recipe and kitchen controls that determine whether a medicine can be scaled, sold and generate revenue.
Precision Timed Release technical
"utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform"
A precision timed release is a drug formulation designed so the active ingredient becomes available at specific, predetermined times after a patient takes a dose, rather than all at once. Like a timed sprinkler that waters different zones on schedule, it can improve how well a medicine works, reduce side effects, and make dosing more convenient—factors that affect regulatory approval, patent protection, market differentiation and ultimately a product’s commercial value for investors.
505(b)(2) pathway regulatory
"CTx-1301 is being evaluated for the treatment of ADHD under the FDA’s 505(b)(2) pathway"
A 505(b)(2) pathway is a U.S. regulatory route that lets a drug developer get approval by relying in part on existing clinical data or published studies instead of repeating every test. Think of it as building on someone else’s homework to shorten development time and cost. For investors, it signals potentially faster, lower‑risk market entry and a chance for competitive protection compared with starting brand‑new drug approvals.
Prescription Drug User Fee Act regulatory
"had assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026"
A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.
FAQ
What did the FDA communicate to Cingulate (CING) about CTx-1301?
The FDA issued a Complete Response Letter for Cingulate’s NDA for CTx-1301. The letter identifies specific Chemistry, Manufacturing and Controls information requests that must be addressed before approval, delaying potential U.S. marketing of this once-daily ADHD treatment.
Did the FDA raise safety or efficacy concerns about CTx-1301 for ADHD?
The FDA’s letter did not raise current concerns about the clinical safety or efficacy of CTx-1301. Instead, it focused on Chemistry, Manufacturing and Controls information, suggesting the main issues lie in manufacturing data and documentation rather than clinical performance.
What are Cingulate’s next steps after receiving the FDA CRL for CTx-1301?
Cingulate plans a prompt resubmission to the FDA with additional Chemistry, Manufacturing and Controls information. The company’s priority is completing CMC work with its manufacturing partner and addressing all outstanding requests so the NDA can re-enter review for potential approval.
How much cash does Cingulate have to support the CTx-1301 resubmission?
Cingulate states it has nearly $30 million in cash reserves. Management believes this capital is sufficient to complete the requested CMC work, execute on the resubmission process, and continue pre-commercial activities for CTx-1301 into 2027 while awaiting further FDA review.
How large is the U.S. ADHD market targeted by CTx-1301?
Cingulate cites an estimated 100 million annual prescriptions in the U.S. ADHD market. Over 20 million patients are diagnosed, including 12 million adults and more than 8 million under 17, indicating a substantial population that might benefit from once-daily treatment options.
What was the original FDA review timeline for CTx-1301?
In October 2025, Cingulate announced the FDA had accepted the NDA for CTx-1301 and assigned a PDUFA target action date of May 31, 2026. The subsequent Complete Response Letter means approval was not granted by that target action date.